Wojciech Krajewski1, Oscar Rodríguez Faba2, Alberto Breda3, Francesca Pisano3, Sławomir Poletajew4, Andrzej Tukiendorf5, Romuald Zdrojowy1, Anna Kołodziej1, Juan Palou3. 1. Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland. 2. Department of Urology, Fundacion Puigvert, Autonomous University of Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain. ORODRIGUEZ@fundacio-puigvert.es. 3. Department of Urology, Fundacion Puigvert, Autonomous University of Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain. 4. Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. 5. Social Medicine Department, Wrocław Medical University, Wrocław, Poland.
Abstract
PURPOSE: The aim of this study was to analyse the influence of age on the treatment outcome and toxicity in patients with T1HG non-muscle invasive bladder cancers treated with BCG immunotherapy. METHODS: Data from 637 patients with primary T1HG bladder cancer who were treated between 1986 and 2016 in two academic centres were retrospectively reviewed. Median follow-up was 57 months. Patients were divided into two groups: younger (< 70 years old) and older (≥ 70 years old). Additional analyses in subgroups of older (> 75 and > 80) patients were performed. Log-rank test, Cox regression analysis, and propensity score matching were performed to compare the groups. RESULTS: There were 389 patients below and 248 patients above or equal 70 years old. Recurrence-free, progression-free, and cancer-specific survival rates did not differ significantly between younger and older patients. Recurrence-free survival for younger and older patients were 55.4% vs 52.9%, progression-free survival 75.9% vs 76.6%, and cancer-specific survival were 87.5% vs 89.9% (all p > 0.05). Differences in the oldest subgroups also did not reach statistical significance. In both regression analysis and propensity score matching, no statistically significant associations of age with any of analysed end-points were found. Finally, there were no statistically significant differences between younger and older group in terms of moderate and severe complications occurrence (47.6% vs. 44.5%; p > 0.05) CONCLUSIONS: It was shown that increasing age was not associated with BCG immunotherapy oncological outcomes, or with BCG toxicity in T1HG non-muscle invasive bladder cancer.
PURPOSE: The aim of this study was to analyse the influence of age on the treatment outcome and toxicity in patients with T1HG non-muscle invasive bladder cancers treated with BCG immunotherapy. METHODS: Data from 637 patients with primary T1HG bladder cancer who were treated between 1986 and 2016 in two academic centres were retrospectively reviewed. Median follow-up was 57 months. Patients were divided into two groups: younger (< 70 years old) and older (≥ 70 years old). Additional analyses in subgroups of older (> 75 and > 80) patients were performed. Log-rank test, Cox regression analysis, and propensity score matching were performed to compare the groups. RESULTS: There were 389 patients below and 248 patients above or equal 70 years old. Recurrence-free, progression-free, and cancer-specific survival rates did not differ significantly between younger and older patients. Recurrence-free survival for younger and older patients were 55.4% vs 52.9%, progression-free survival 75.9% vs 76.6%, and cancer-specific survival were 87.5% vs 89.9% (all p > 0.05). Differences in the oldest subgroups also did not reach statistical significance. In both regression analysis and propensity score matching, no statistically significant associations of age with any of analysed end-points were found. Finally, there were no statistically significant differences between younger and older group in terms of moderate and severe complications occurrence (47.6% vs. 44.5%; p > 0.05) CONCLUSIONS: It was shown that increasing age was not associated with BCG immunotherapy oncological outcomes, or with BCG toxicity in T1HG non-muscle invasive bladder cancer.
Authors: Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner Journal: Eur Urol Date: 2016-06-17 Impact factor: 20.096
Authors: Jesus Fernandez-Gomez; Rosario Madero; Eduardo Solsona; Miguel Unda; Luis Martinez-Piñeiro; Marcelino Gonzalez; Jose Portillo; Antonio Ojea; Carlos Pertusa; Jesus Rodriguez-Molina; Jose Emilio Camacho; Mariano Rabadan; Ander Astobieta; Manuel Montesinos; Santiago Isorna; Pedro Muntañola; Anabel Gimeno; Miguel Blas; Jose Antonio Martinez-Piñeiro Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Jorg R Oddens; Richard J Sylvester; Maurizio A Brausi; Wim J Kirkels; Cees van de Beek; George van Andel; Theo M de Reijke; Stephen Prescott; J Alfred Witjes; Willem Oosterlinck Journal: Eur Urol Date: 2014-06-16 Impact factor: 20.096
Authors: Mihaela Georgiana Musat; Christina Soeun Kwon; Elizabeth Masters; Slaven Sikirica; Debduth B Pijush; Anna Forsythe Journal: Clinicoecon Outcomes Res Date: 2022-01-10